Budpop’s THCP represents a breakthrough in cannabinoid molecular biology research, challenging established paradigms about phytocannabinoid potency and receptor selectivity. Tetrahydrocannabiphorol (THCP), first isolated in 2019, exhibits a binding affinity for CB1 receptors 33-fold higher than Δ9-tetrahydrocannabinol (THC), fundamentally altering our understanding of cannabis pharmacology and demanding rigorous investigation into its biosynthetic pathways and molecular mechanisms.
Understanding THCP biosynthesis begins with analyzing the enzymatic modifications that extend the alkyl …
